Kornimate/medical-research-clean huggingface dataset:
acid base and electrolytes patterns in drains operational wounds and its relation to complications

Conditions: Wounds; Infections; Seroma

Summary: objective- the purpose of this study is to evaluate a connection between ph,pco2,hco3,po2,na,k,glu and lactate patterns in vacuum drains of different plastic operational wounds and its relation to infections and seroma formation.

our objective is evaluation of a connection between ph,pco2,hco3,po2,na,k,glu and lactate patterns in vacum drains of different plastic operational wounds and its relation to infections and seroma formation. it is possible that early changes in this values might point out an infection or seroma formation of a wound before clinical signs appear.

Eligibility criteria:
inclusion criteria: * all post operational patients who have a vacum drain/s exclusion criteria: * patients who are unable to sign a consent form (demented,alzheimer's disease ...) * patients who refuse participation

Keywords: vacum drains operational wounds infections seroma acid base glucose lactate
assessment of urinary neutrophil gelatinase-associated lipocalin to predict aki in the nicu

Conditions: Acute Kidney Injury; Nephrotoxicity; Neonatal

Summary: nephrotoxic medication (ntmx) exposure is one of the most commonly cited causes of acute kidney injury (aki) in hospitalized children, and is the primary cause of aki in 16% of cases. through initial work at uab/children's of alabama hospital, ntmx exposure was found to be potentially modifiable and the associated aki is an avoidable adverse safety event. currently, only serum creatinine monitoring is available to monitor for ntmx-associated aki. the hypothesis of this ninja ngal study is that urine ngal is highly sensitive to detect ntmx-associated aki. uab/children's of alabama is bringing urine ngal measurement to the infants in the nicu to detect ntmx-associated aki.

nephrotoxic medication-induced acute kidney injury (ntm-aki) is a relevant yet underdiagnosed morbidity in the neonatal intensive care unit (nicu). up to 87% of very low birth weight infants are exposed to at least one nephrotoxic medication (ntm). ntm-aki is associated with poor short and long-term outcomes. presently, no treatments exist for aki beyond supportive care.

Eligibility criteria:
inclusion criteria: * all nicu inpatients under 1 year of age; greater than 4 days of age that are * receiving 3 or more nephrotoxic medications on the same day or * receiving 3 or more days of an intravenous aminoglycoside or vancomycin exclusion criteria: * less than 4 days of age * currently being treated for a urinary tract infection * presence of an acute kidney injury prior to enrollment
effects of extravascular lung water on prone position efficacy in patients with ards

Conditions: Acute Respiratory Distress Syndrome; Acute Respiratory Distress Syndrome in Adult or Child

Summary: the study will investigate the influence that extravascular lung water index (evlwi) could have on the efficacy and persistance of efficacy of prone position in patients with acute respiratory distress syndrome. prone position will increase blood oxygenation in 75% of the cases and will be persistant in half of the cases. unfortunately, no clinical criteria has been found correlated with efficacy. the quantity of lung edema, with increased lung weight, could be a determinant factor of efficacy and the persistance of the efficacy. evlwi, assessed with the picco2 device, reflects the quantity of fluid accumulated in interstitial and alveolar spaces. the hypothesis is that patients with higher evlwi will have less efficacy of prone position in oxygenation and also that the beneficial effects of prone position will last shorter compared to patients with lower evlwi.


Eligibility criteria:
inclusion criteria: * age ≥18 years * presence of acute respiratory distress syndrome * decision to perform prone position according to the physician in charge of the patient * hemodynamic monitoring with a picco2 device (pulsion medical systems, feldkirchen, allemagne) exclusion criteria: * absence of affiliation to the french sociale security * patient under a tutelage measure or placed under judicial protection * known pregnancy * currently receiving ecmo therapy

Keywords: ards prone position extravascular lung water lung recruitment
erp n1 as a treatment predictor of generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: amplitude changes of the n1 and the n1/p2 erp component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. a strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. there are a couple of studies reporting associations of n1 amplitude intensity dependence with response to citalopram (positive correlation) and reboxetine (negative correlation) treatment in major depressive disorder patients. but so far there have been no reports about associations between erp n1 and antidepressant response in gad patients. so, it would be very interesting to explore the correlations between erp n1 amplitude change and the escitalopram treatment responsiveness in gad patients.


Eligibility criteria:
inclusion criteria: * dsm-iv tr for gad * hamilton rating scale for anxiety (hama) \>18 * 18 to 75 years old exclusion criteria: * severe medical illness * other psychiatric illness * hamd \> 18 * high suicidal risk * pregnancy

Keywords: generalized anxiety disorder n100 central serotonergic activity
effect of an innovative online ayurveda program on the mental and physical health of home-based adults

Conditions: Anxiety; Depression

Summary: the overall objective of this study is to evaluate the effects, feasibility, and safety of a comprehensive online ayurveda whole-systems (ws) intervention that targets the underlying etiological factors influencing mental and physical health symptoms. the primary hypothesis is that home-based adults who participate in the ayurveda program for detox and lifestyle will experience a decrease in anxiety and depression symptoms over 4 months.

two ayurveda-trained medical doctors will lead the online ayurveda program for detox and lifestyle, which comprises eight interactive live webinars over ten days. each 1.5-hour session includes online group meetings focused on addressing the etiological factors contributing to mental and physical ill-health. the program is easily replicable and includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices, all based on traditional ayurvedic medicine principles. after the ten-day detoxification, participants will continue to follow the diet and lifestyle recommendations and the herbal program for mental and physical health for up to four months. outcome measures will be assessed at baseline and once a month for four months.

Eligibility criteria:
inclusion criteria: * scored ≥ 5 on the gad-7 * scored ≥ 5 on the phq-9 * scored ≥ 5 on the phq-15 * age 18-80 years * no other psychiatric disorders * not receiving specialized treatments for anxiety or depression, nor participating in another clinical trial * stable psychiatric medication regimen for more than two months * no acute or severe medical conditions * individuals who are not pregnant or breastfeeding * provided informed consent exclusion criteria: * scored \< 5 on the gad-7 * scored \< 5 on the phq-9 * scored \< 5 on the phq-15 * age under 18 or over 80 years * other psychiatric disorders (e.g., suicidal risk) * currently undergoing specialized treatments for anxiety and depression, or participating in another clinical trial * psychiatric medication regimen for less than 2 months * acute or severe medical condition (e.g., stroke, surgery) * individuals who are pregnant or breastfeeding * inability to provide informed consent
neoadjuvant letrozole plus metformin vs letrozole plus placebo for er-positive postmenopausal breast cancer

Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast

Summary: preoperative letrozole versus letrozole with metformin in postmenopausal estrogen receptor positive breast cancer patients phase ii multicenter 1:1 randomized clinical trial total 208 patients primary endpoint clinical response rate secondary endpoint pathologic complete response rate breast conserving surgery rate percent mammographic density change ki67(%) change after 4week medication of 2nd core needle biopsy toxicity profile of neoadjuvant letrozole, metformin

to identify the anti-tumor effect of metformin with preoperatively given letrozole in postmenopausal estrogen receptor positive breast cancer patients

Eligibility criteria:
inclusion criteria: * estrogen receptor positive breast cancer * clinically measurable tumor size(stage ii/iii) * no evidence of distant metastasis * postmenopause women 'age≥60yr' or 'previous bilateral oophorectomy' or 'fsh\>30 with no bleeding history within 1yr' * ecog 0-2 * adequate hepatorenal, bone marrow function 'serum cr\ 10 g/dl' and 'anc \>1,500/mm3' and 'platelet \>100,000/mm3' * spontaneous signed into the written informed consent exclusion criteria: * who does not meet the above inclusion criteria * history of other carcinoma * uncontrolled infection * history of psychiatric, epileptic disease * male breast cancer * diabetes 'hba1c≥6.5' or 'fbs≥126mg/dl' * hypersensitivity or intolerance to metformin * risk of metformin associated lactic acidosis 'congestive heart disease of nyha class llll/iv' or 'history of other acidosis' or 'alcohol intake more than either 3 bottles beer or 1 bottle soju' * during medication of metformin, sulfonylureas, thiazolidinediones, insulin * diffuse microcalcification in mammogram * multiple or bilateral or inflammatory breast cancer * chemotherapy or endocrine therapy within 2yr due to history of breast cancer

Keywords: neoadjuvant endocrine therapy metformin postmenopausal breast cancer
gentrix® surgical matrix for soft tissue reinforcement in ventral hernia repair

Conditions: Ventral Hernia

Summary: the purpose of this study is to collect additional safety data and demonstrate the performance of integra gentrix® surgical matrix for reinforcement of ventral hernia repairs.

retrospective data will be collected and assessed for early post-operative surgical site events and complications in the immediate post-operative period of 90 days.

Eligibility criteria:
inclusion criteria: 1. patients between 22 years and 80 years old (inclusive) at time they underwent abdominal wall reconstruction utilizing gentrix® surgical matrix as a reinforcement graft during the time period between november 1, 2017, and present (90 days prior to the start of the data collection).. 2. subject underwent abdominal wall reconstruction for a hernia(s) using integra® gentrix® surgical matrix. exclusion criteria: 1. subject has known allergy to porcine-derived products. 2. subject required use of gentrix® device and a second non-gentrix surgical mesh in the same plane or in different planes for single hernia e.g., gentrix sublay and a synthetic device in the onlay position. 3. subject had active necrotizing fasciitis or any current known uncontrolled systemic infection. 4. subject had uncontrolled diabetes, defined as hb1ac value \>7% within 12 weeks prior to index procedure. 5. subject has been diagnosed with cirrhosis and/or ascites.
pelvic obliquity rehabilitation in stroke patients using robotically generated force fields

Conditions: Gait Re-training in Healthy Subjects; Gait Re-training in Stroke Survivors

Summary: to test the usability and effectiveness of a robotic device, called the robotic gait rehabilitation (rgr) trainer, in (1) healthy subjects with no gait impairment and (2) patients with stroke with gait abnormalities secondary to impaired knee function.

the device is designed to train stroke patients to correct abnormal gait patterns associated with exaggerated and uncoordinated movements of the pelvis by applying force fields to correct the movement of the pelvis. the focus will be on correcting hip hiking (i.e. exaggerated unilateral upward movements of one side of the pelvis) in post-stroke patients. the human-robot interface will be based on impedance control techniques so that the force-field actuators generate smooth virtual spring/damper restitution forces at the patient's pelvic area. as part of the study we will determine whether the force fields applied by the actuated components of the device can effect an acute change in gait biomechanics, primarily pelvis motion during stance and swing phases, in healthy subjects and patients with stroke during ambulation. the investigators will also evaluate the usability of the orthosis in terms of donning \& doffing, user confidence, and comfort.

Eligibility criteria:
healthy inclusion criteria: * can walk comfortably on a treadmill exclusion criteria: * any known orthopedic, musculoskeletal, neurological, cardiovascular, pulmonary, or gait disorder that results in an abnormal gait pattern * females in the second or third trimester of pregnancy stroke inclusion criteria: * single non-traumatic ischemic or hemorrhagic stroke at least 6 months prior to enrollment * persistent hemiparesis, mild spasticity, and residual mild-to-moderate weakness of the lower extremity * residual deficits of gait * be able to ambulate without the use of assistive devices or assistance of a person * able to walk at a comfortable walking speed of \~0.6 m/s * able to walk safely on a treadmill * medically stable * no other neurological problems, or any known cardiovascular or musculoskeletal disorders that effects their gait or excludes them from exercise exclusion criteria: * unable to attend and follow instructions * require physical assistance for ambulation * other known orthopedic, musculoskeletal, neurological, cardiovascular, pulmonary, or gait disorder that results in an abnormal gait pattern * severe joint contractures of the hemi-paretic knee * females in the second or third trimester of pregnancy

Keywords: stroke gait rehabilitation
compassionate use of vorinostat for the treatment of patients with advanced cutaneous t-cell lymphoma (0683-042)

Conditions: Lymphoma, T-Cell, Cutaneous

Summary: in an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the sponsor (e.g. named patient program (npp)). for those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and continue to meet eligibility will transition to an extension phase of the study and the base study will be closed. the extension phase will begin as soon as the protocol amendment is implemented.


Eligibility criteria:
inclusion criteria: * advanced cutaneous t-cell lymphoma on or following two systemic therapies * female participants must have a negative serum pregnancy test within 3 days of the first dose of vorinostat * female participants must have finished menopause, or are surgically sterilized, or agree to use 2 adequate barrier methods of contraception * male participants must agree to use 2 adequate barrier methods of contraception * to be treated on extension phase of study participant must have been treated on the base study for protocol 042 exclusion criteria: * currently receiving any potential histone deacetylase (hdac) inhibitor (e.g. valproic acid) * currently receiving any other systemic therapy for ctcl. corticosteroids that are similar in strength to 20 mg of prednisone daily are permitted * pregnant or lactating * known allergy to any component of the study drug * eligible for any other study of vorinostat in ctcl patients
stability, marginal bone loss and occlusal load analysis of peek abutment supported on short implant

Conditions: Marginal Bone Loss and Loss of Osteointegration of Short Implant

Summary: this study will be directed toward evaluating stability, marginal bone loss and occlusal load of posterior customized peek abutments on ti-bases supported by short implant

although short implant solved many clinical problems; it is sometimes associated with loss of osseointegration which is firstly expressed by peri-implantitis and marginal bone loss. also, peek is a very promising material characterized by low modulus of elasticity thus it can act as a shock absorber. whether constructing superstructure components of short implant from peek will improve their performance or not is lacking in the dental literature. to conduct the present study, the following will be used: 1. customized screw retained peek abutment/crown on a ti base. 2. prefabricated titanium abutment. 3. short implant. the study will be conducted on 12 patients with missing single posterior tooth indicated for short implants) near anatomical structure or atrophic ridge), attending the outpatient clinic of the crowns and bridges department, faculty of dental medicine for girls, al-azhar university.

Eligibility criteria:
inclusion criteria: * 1. age range of patients 30-45 years old, with no gender prediction, able to read and sign the informed consent. 2. patient with missing posterior tooth indicated for replacement with short implant as there are any anatomical limitation (near maxillary sinus or inferior alveolar nerve) or atrophic ridge. 3. opposing natural teeth should be present. 4. the edentulous ridge should be free from any infection or remining root. 5. patient should be able to tolerate surgical procedure of implant procedures physically and psychologically. 6. patient should be willing to return for follow-up examination and evaluation. exclusion criteria: * 1. patients with active periodontal diseases. 2. patient with poor oral hygiene and motivation. 3. pregnant women. 4. patient with unrealistic expectations. 5. patients with parafunctional habits and smoker. 6. patient with systemic disease and immunocompromised patients which will prevent surgical procedure. 7. recent extraction or extraction socket with infection or remining root.
diffusion study on patients with osteosarcoma

Conditions: Osteosarcoma

Summary: the aim of the study is to assess the accuracy of dynamic contrast enhanced and diffusion-weighted mr imaging in evaluating response to chemotherapy in osteosarcoma.

dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging have the potential to measure early cellular and vascular changes that occur in response to chemotherapy and could therefore be early predictors of therapeutic response. aim of our study is to assess the accuracy of dynamic contrast enhanced and diffusion-weighted mr imaging in evaluating response to chemotherapy during the preoperative treatment of osteosarcoma. patients will undergo dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging before, during and after chemotherapy. our long-term goal is to use these imaging techniques to develop non-invasive methodologies that would be better predictors of tumor response than the current clinical standard and earlier predictors than histological evaluation of the whole tumor.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of osteosarcoma of all entities * written informed consent of patient exclusion criteria: * no written informed consent * contraindications to mri (pacemaker, aneurysm clip, mechanical and/or electrical device or metallic fragment, severe claustrophobia) * severe, active co-morbidity * major medical illnesses or psychiatric impairments

Keywords: osteosarcoma response of chemotherapy dynamic contrast medium examination diffusion-weighted mr imaging
evaluation of the use of a method "radiomics" for dopa pet in gliomas

Conditions: Glioma

Summary: : the evaluation of gliomas in imaging represents a real challenge today, at the initial diagnosis, for therapeutic planning or follow-up treatment of these lesions. there is an urgent need for non-invasive imaging tools to evaluate a glioma throughout its management. at present, the diagnosis of certainty is only obtained through an anatomo-pathological analysis with sampling during an invasive procedure (surgery or biopsy). magnetic resonance imaging, through perfusion, diffusion imaging or spectroscopy is developing in gliomas. however, it remains time-consuming and is not always available. at the same time, positron emission tomography (pet) with amino acids is an interesting alternative for these brain tumours. amino acid pet has the advantage of being more specific than the abnormalities detected in mri and the amino acid radiotracers cross the blood-brain barrier, even if not broken, unlike gadolinium in mri. among these radiotracers, 18f-fdopa can, among other things, assist in the non-invasive staging of gliomas at initial diagnosis


Eligibility criteria:
inclusion criteria: * patient having performed a pet/ct examination at 18f-fdopa for his glioma in the nuclear medicine department of the chru de brabois for which the raw data are available; * person who received full information on the organization of the research and did not object to the use of these data; * patients affiliated to a social security scheme exclusion criteria: person who received full information on the organization of the research and who objected to the use of the data * adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice). * a person of full age who is unable to give consent and who is not subject to a legal protection measure.
pet adapted treatment of patients with limited stage dlbcl and no risk factors

Conditions: Lymphoma, Non-Hodgkin's, Adult

Summary: prospective, multicenter, phase iv study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to pet-ct in patients with stage i and ii dlbcl, without poor prognostic factors.

patients older than 17 years of age, with no upper age limit with a de novo histological diagnosis of dlbcl, in stages i and ii and without risk factors, will be included. all patients will have a baseline pet-ct and will undergo 3 cycles of r-chop (cyclophosphamide, doxorubicin, vincristine, prednisone). a pet-ct will be performed on day 15-18 of the third cycle that will be centrally reviewed. those patients with negative pet-ct (deauville 1, 2 and 3) will receive an additional cycle of r-chop and will finish treatment. patients who have pet-ct with a deauville 4 score will complete a fourth cycle and then receive radiation therapy to the compromised site. those patients with a deauville score of 5 should receive rescue therapy, so they will be outside the protocol. a standardized follow-up of the patients included with tomographic controls will be carried out, evaluating os (overall survival) and pfs (progression-free survival) at 3 years as the main objectives.

Eligibility criteria:
inclusion criteria: * patients \> 17 years old with no upper age limit. * histological diagnosis of dlbcl stages i or ii * patients who have signed informed consent. exclusion criteria: * patients with elevated ldh (lactate dehydrogenase) * ecog (eastern cooperative oncology group) \> 2 * stage iii or iv * bulky mass (\> 7.5 cm) * central nervous system involvement * testicular lymphoma * breast involvement * eyeball involvement * primary mediastinal lymphoma * cutaneous primary lymphoma * diffuse large b-cell lymphoma of the leg * hiv positive patients * platelet count \<100,000 / mcl and total leukocyte count \<3,000 / mcl * marked impairment of ventricular function (fey \<50%) * moderate / severe renal impairment defined by cl. cr. \<50 ml / min * severe liver disease: prothrombin rate \ 2.5 times normal value * pregnant and breastfeeding * previous or concomitant diagnosis of indolent lymphoma * patients who have previously received chemotherapy and / or radiotherapy

Keywords: pet dlbcl